Decoy (DCOY) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

$227,629.00

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$2.4M

Net income growth (year over year)

−147.83%

Net margin

—

Return on equity

−827.77%

EPS (trailing twelve months)

$115.98

Book value per share

$8.12

P/E (trailing twelve months)

—

Price to book

0.68

Debt to assets

52.00%

Payout ratio

—

Dividend yield

—

Company profile

Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

• How do I buy stock in Decoy (DCOY)?

  DCOY trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.